Key Data Updates in HR+/HER2- Breast Cancer from SABCS 2023

home / data-dialogue-with-the-oncology-brothers / key-data-updates-in-hr-her2-breast-cancer-from-sabcs-2023

Following the 2023 San Antonio Breast Cancer Symposium, Hope Rugo, MD joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss key clinical trial data updates in HR+, HER2- Breast Cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

EP. 1: Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Hope S. Rugo, MD
January 8th 2024

Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

EP. 2: MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Hope S. Rugo, MD
January 8th 2024

Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

EP. 3: Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Hope S. Rugo, MD
January 8th 2024

Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

EP. 4: TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Hope S. Rugo, MD
January 8th 2024

Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.

Rahul Gosain, MD; Rohit Gosain, MD; and Hope Rugo, MD, presenting slides

EP. 5: Key Takeaways from SABCS 2023

Rahul Gosain, MD;Rohit Gosain, MD;Hope S. Rugo, MD
January 8th 2024

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in HR+/HER2- breast cancer.